1057 related articles for article (PubMed ID: 28511092)
1. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
2. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
3. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
4. Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?
Schnekenburger M; Dicato M; Diederich MF
Cancer; 2019 May; 125(10):1612-1628. PubMed ID: 30840315
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
6. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
7. Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?
Ali MA; Matboli M; Tarek M; Reda M; Kamal KM; Nouh M; Ashry AM; El-Bab AF; Mesalam HA; Shafei AE; Abdel-Rahman O
Immunotherapy; 2017 Jan; 9(1):99-108. PubMed ID: 28000527
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
Adachi K; Tamada K
Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation in cancer immunotherapy.
Gallagher SJ; Shklovskaya E; Hersey P
Curr Opin Pharmacol; 2017 Aug; 35():48-56. PubMed ID: 28609681
[TBL] [Abstract][Full Text] [Related]
13. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower KJ; Ghaem-Maghami S; Brown R
Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment.
Garcia-Gomez A; Rodríguez-Ubreva J; Ballestar E
Clin Immunol; 2018 Nov; 196():64-71. PubMed ID: 29501540
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
[TBL] [Abstract][Full Text] [Related]
16. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
[TBL] [Abstract][Full Text] [Related]
18. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
20. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R; Zwergel C; Mai A; Valente S
Clin Epigenetics; 2017; 9():59. PubMed ID: 28572863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]